Emergent Biosolutions Company Profile (NYSE:EBS)

About Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions logoEmergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NYSE:EBS
  • CUSIP: 29089Q10
  • Web: www.emergentbiosolutions.com
Capitalization:
  • Market Cap: $1.4296 billion
  • Outstanding Shares: 40,974,000
Average Prices:
  • 50 Day Moving Avg: $33.28
  • 200 Day Moving Avg: $31.00
  • 52 Week Range: $24.47 - $36.64
P/E:
  • Trailing P/E Ratio: 28.65
  • Foreward P/E Ratio: 18.77
  • P/E Growth: 1.35
Sales & Book Value:
  • Annual Revenue: $502.68 million
  • Price / Sales: 2.94
  • Book Value: $14.90 per share
  • Price / Book: 2.42
Profitability:
  • EBIDTA: $150.22 million
  • Net Margins: 10.36%
  • Return on Equity: 11.92%
  • Return on Assets: 7.40%
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 7.23%
  • Quick Ratio: 6.18%
Misc:
  • Average Volume: 292,460 shs.
  • Beta: 1.21
  • Short Ratio: 8.64
 

Frequently Asked Questions for Emergent Biosolutions (NYSE:EBS)

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions, Inc. (NYSE:EBS) announced its earnings results on Thursday, May, 4th. The company reported $0.23 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.31 by $0.08. The firm had revenue of $116.90 million for the quarter, compared to the consensus estimate of $121.30 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. Emergent Biosolutions's revenue for the quarter was up 13.5% on a year-over-year basis. During the same quarter last year, the business posted $0.16 EPS. View Emergent Biosolutions' Earnings History.

Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?

4 brokerages have issued 1 year target prices for Emergent Biosolutions' shares. Their predictions range from $33.00 to $47.00. On average, they anticipate Emergent Biosolutions' stock price to reach $39.25 in the next twelve months. View Analyst Ratings for Emergent Biosolutions.

What are analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:

  • 1. According to Zacks Investment Research, "Emergent’s key drug BioThrax is from the company’s Biodefense segment. The U.S. government is the primary purchaser of its Biodefense products. Hence, the company’s sole dependence on BioThrax for its revenue is concerning. Moreover, Emergent faces competition from a number of companies with Biodefense products, which could adversely affect the company’s operating results. Shares of the company have underperformed the broader industry so far this year. However, the company’s follow-on contract with the CDC for BioThrax and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/17/2017)
  • 2. Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)
  • 3. J P Morgan Chase & Co analysts commented, "This afternoon, Emergent announced 2Q financial results, and while a great deal of focus remains on the upcoming BioThrax and NuThrax contracts, details were limited on these topics and 2016 guidance will not be reinstated until the outcomes are known. While we continue to see high probability of approval for Building 55 (Aug 15 PDUFA date), we believe the Street will need incremental clarity, particularly visibility on pricing in the next BioThrax contract and some color on expectations for the near-term delivery schedule, for the overhang on EBS shares to begin to lift. That said, this clarity is not far off, and we expect an update on both BioThrax and NuThrax by the end of September." (8/5/2016)

Who are some of Emergent Biosolutions' key competitors?

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the folowing people:

  • Fuad El-Hibri, Executive Chairman of the Board
  • Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director
  • Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer
  • Adam Havey, Executive Vice President - Business Operations
  • Ronald B. Richard, Lead Independent Director
  • Sue Bailey M.D., Independent Director
  • Zsolt Harsanyi Ph.D., Independent Director
  • Jerome M. Hauer, Independent Director
  • George A. Joulwan USA, Independent Director

Who owns Emergent Biosolutions stock?

Emergent Biosolutions' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.97%), Peregrine Capital Management LLC (0.79%), Bank of Montreal Can (0.21%), US Bancorp DE (0.10%), Eqis Capital Management Inc. (0.09%) and Nisa Investment Advisors LLC (0.09%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?

Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC, Peregrine Capital Management LLC, Capstone Asset Management Co., Nisa Investment Advisors LLC and US Bancorp DE. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Jerome M Hauer, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.

Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?

Emergent Biosolutions' stock was acquired by a variety of institutional investors in the last quarter, including Capital Asset Advisory Services LLC, State of Alaska Department of Revenue, Aperio Group LLC, Eqis Capital Management Inc., Louisiana State Employees Retirement System and Creative Planning. View Insider Buying and Selling for Emergent Biosolutions.

How do I buy Emergent Biosolutions stock?

Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of Emergent Biosolutions stock can currently be purchased for approximately $36.04.


MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Emergent Biosolutions (NYSE:EBS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $39.25 (8.91% upside)

Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/30/2017Chardan CapitalReiterated RatingBuy$47.00N/AView Rating Details
1/9/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
10/1/2016Wells Fargo & CompanySet Price TargetBuy$41.00N/AView Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetOverweight$45.00 -> $36.00N/AView Rating Details
6/28/2016Singular ResearchLower Price TargetBuy$44.00 -> $40.00N/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Emergent Biosolutions (NYSE:EBS)
Earnings by Quarter for Emergent Biosolutions (NYSE:EBS)
Earnings History by Quarter for Emergent Biosolutions (NYSE EBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017$0.31$0.23$121.30 million$116.90 millionViewListenView Earnings Details
2/23/2017Q4 2016$0.48$0.74$120.45 million$151.66 millionViewListenView Earnings Details
11/7/2016Q3$0.26$0.58$112.30 million$142.91 millionViewListenView Earnings Details
8/4/2016Q2($0.17)($0.18)$111.20 million$101.49 millionViewListenView Earnings Details
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details
2/25/2016Q4$0.69$0.78$168.07 million$168.10 millionViewListenView Earnings Details
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details
5/7/2015Q1($0.46)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details
3/5/2015Q115$0.97$0.75$147.00 million$148.00 millionViewListenView Earnings Details
11/6/2014Q414$0.37$0.67$126.90 million$138.00 millionViewListenView Earnings Details
8/7/2014Q214$0.26$0.24$109.25 million$110.30 millionViewListenView Earnings Details
5/8/2014Q114($0.34)($0.40)$57.30 million$53.90 millionViewListenView Earnings Details
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details
8/2/2012$0.21$0.21ViewN/AView Earnings Details
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details
3/8/2012$0.72$0.78ViewN/AView Earnings Details
11/3/2011($0.04)$0.04ViewN/AView Earnings Details
8/4/2011$0.33$0.40ViewN/AView Earnings Details
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details
3/10/2011$0.67$0.76ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Emergent Biosolutions (NYSE:EBS)
Current Year EPS Consensus Estimate: $1.51 EPS
Next Year EPS Consensus Estimate: $1.92 EPS

Dividends

Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Emergent Biosolutions (NYSE:EBS)
Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 85.89%
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)
Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Adam HaveyEVPSell11,419$28.62$326,811.78View SEC Filing  
3/8/2017Jerome M HauerDirectorSell2,576$31.27$80,551.52View SEC Filing  
1/17/2017Adam HaveyEVPSell8,438$29.75$251,030.50View SEC Filing  
1/17/2017Sue BaileyDirectorSell19,424$29.78$578,446.72View SEC Filing  
1/10/2017Daniel Abdun-NabiInsiderSell28,240$31.28$883,347.20View SEC Filing  
12/13/2016Ronald RichardDirectorSell5,900$34.09$201,131.00View SEC Filing  
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.00View SEC Filing  
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26View SEC Filing  
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.50View SEC Filing  
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.67View SEC Filing  
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.00View SEC Filing  
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.11View SEC Filing  
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.00View SEC Filing  
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.00View SEC Filing  
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00View SEC Filing  
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.48View SEC Filing  
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.51View SEC Filing  
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.00View SEC Filing  
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.00View SEC Filing  
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.25View SEC Filing  
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.50View SEC Filing  
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34View SEC Filing  
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.50View SEC Filing  
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.00View SEC Filing  
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.40View SEC Filing  
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.20View SEC Filing  
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.32View SEC Filing  
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.64View SEC Filing  
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.00View SEC Filing  
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.08View SEC Filing  
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.37View SEC Filing  
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.28View SEC Filing  
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.80View SEC Filing  
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.00View SEC Filing  
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54View SEC Filing  
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.50View SEC Filing  
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.50View SEC Filing  
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.64View SEC Filing  
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.50View SEC Filing  
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.00View SEC Filing  
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.50View SEC Filing  
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.60View SEC Filing  
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.26View SEC Filing  
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.00View SEC Filing  
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Emergent Biosolutions (NYSE:EBS)
Latest Headlines for Emergent Biosolutions (NYSE:EBS)
Source:
DateHeadline
globenewswire.com logoEmergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 3:25 PM
finance.yahoo.com logoEmergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
finance.yahoo.com - July 20 at 3:25 PM
finance.yahoo.com logoEmergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
finance.yahoo.com - July 19 at 9:18 PM
zacks.com logoEmergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
www.zacks.com - July 17 at 7:01 PM
finance.yahoo.com logoEmergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
finance.yahoo.com - July 17 at 7:01 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:26 PM
rttnews.com logoEmergent BioSolutions To Buy ACAM2000 Business From Sanofi For Up To $125 Mln
www.rttnews.com - July 16 at 5:28 PM
globenewswire.com logoEmergent BioSolutions to Acquire ACAM2000® Business From Sanofi - GlobeNewswire (press release)
globenewswire.com - July 14 at 4:09 PM
finance.yahoo.com logoEmergent BioSolutions to Acquire ACAM2000® Business From Sanofi
finance.yahoo.com - July 14 at 4:09 PM
finance.yahoo.com logoEmergent acquires Sanofi smallpox vaccine in deal worth up to $125 million
finance.yahoo.com - July 14 at 4:09 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 10:53 AM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - June 24 at 7:20 PM
nasdaq.com logoWhy Is Emergent Biosolutions (EBS) Up 3.9% Since the Last ... - Nasdaq
www.nasdaq.com - June 9 at 5:19 PM
finance.yahoo.com logoWhy Is Emergent Biosolutions (EBS) Up 3.9% Since the Last Earnings Report?
finance.yahoo.com - June 9 at 5:19 PM
finance.yahoo.com logoETFs with exposure to Emergent BioSolutions, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 5:15 PM
nasdaq.com logoNoteworthy Tuesday Option Activity: EBS, WNR, LNG
www.nasdaq.com - May 30 at 4:45 PM
finance.yahoo.com logoEmergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : May 24, 2017
finance.yahoo.com - May 24 at 12:25 PM
nasdaq.com logoEBS Crosses Below Key Moving Average Level
www.nasdaq.com - May 22 at 4:37 PM
seekingalpha.com logoEmergent BioSolutions (EBS) Presents At Three Part Advisors 2017 East Coast IDEAS Investor Conference - Slideshow
seekingalpha.com - May 22 at 4:37 PM
finance.yahoo.com logoETFs with exposure to Emergent BioSolutions, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:37 PM
finance.yahoo.com logoEmergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 4:42 PM
americanbankingnews.com logoEmergent Biosolutions Inc (EBS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 16 at 8:58 AM
globenewswire.com logoEmergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in ... - GlobeNewswire (press release)
globenewswire.com - May 11 at 10:38 PM
finance.yahoo.com logoEmergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore
finance.yahoo.com - May 10 at 5:01 PM
finance.yahoo.com logoEmergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
finance.yahoo.com - May 9 at 7:19 AM
seekingalpha.com logoEmergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 8 at 4:45 PM
fool.com logoEmergent Biosolutions Inc. Moves Things Around, Still Sees Growth
www.fool.com - May 8 at 4:34 PM
finance.yahoo.com logoEmergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : May 8, 2017
finance.yahoo.com - May 8 at 9:19 AM
finance.yahoo.com logoEdited Transcript of EBS earnings conference call or presentation 4-May-17 9:00pm GMT
finance.yahoo.com - May 5 at 5:04 PM
americanbankingnews.com logoEmergent Biosolutions Inc (EBS) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 12:00 AM
marketbeat.com logoEmergent Biosolutions beats 1Q profit forecasts
marketbeat.com - May 4 at 7:17 PM
finance.yahoo.com logoEmergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
finance.yahoo.com - May 4 at 5:01 PM
americanbankingnews.com logoEmergent Biosolutions (EBS) Getting Very Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 7:39 AM
finance.yahoo.com logoEmergent BioSolutions, Inc. – Value Analysis (NYSE:EBS) : April 27, 2017
finance.yahoo.com - April 27 at 5:25 PM
finance.yahoo.com logoEmergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : April 26, 2017
finance.yahoo.com - April 26 at 11:54 PM
americanbankingnews.com logoEmergent Biosolutions (EBS) Earns Coverage Optimism Score of -0.22
www.americanbankingnews.com - April 25 at 12:03 PM
americanbankingnews.com logoEmergent Biosolutions (EBS) Receiving Positive News Coverage, Report Shows
www.americanbankingnews.com - April 22 at 2:49 PM
americanbankingnews.com logoEmergent Biosolutions Inc (EBS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 21 at 9:47 AM
globenewswire.com logoEmergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017 - GlobeNewswire (press release)
globenewswire.com - April 20 at 8:38 AM
finance.yahoo.com logoEmergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
finance.yahoo.com - April 20 at 8:38 AM
americanbankingnews.com logoEmergent Biosolutions (EBS) Receiving Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 16 at 9:08 AM
americanbankingnews.com logoInsider Selling: Emergent Biosolutions Inc (EBS) EVP Sells 11,419 Shares of Stock
www.americanbankingnews.com - April 4 at 8:37 PM
globenewswire.com logoEmergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin - GlobeNewswire (press release)
globenewswire.com - April 2 at 8:36 AM
streetinsider.com logoEmergent BioSolutions (EBS) Agrees to $53M BARDA Contract Modification for Supply of Botulism Antitoxin - StreetInsider.com
www.streetinsider.com - April 1 at 8:36 AM
us.rd.yahoo.com logoEmergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
us.rd.yahoo.com - March 31 at 4:57 PM
americanbankingnews.com logoEmergent Biosolutions Inc (EBS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 27 at 1:08 PM
seekingalpha.com logoEmergent BioSolutions: Underlying Value To Be Realized Following Aptevo Spin-Off
seekingalpha.com - March 26 at 10:02 AM
bizjournals.com logoEmergent BioSolutions Inc. (NYSE: EBS) gets $100 million anthrax ... - Washington Business Journal
www.bizjournals.com - March 20 at 7:44 PM
bizjournals.com logoEmergent BioSolutions gets $100 million anthrax contract from feds
www.bizjournals.com - March 20 at 7:44 PM
globenewswire.com logoEmergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile - GlobeNewswire (press release)
globenewswire.com - March 19 at 4:30 PM

Social

Chart

Emergent Biosolutions (EBS) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff